Floatz logo

PBR-06

Stroke

University Hospital, BordeauxSmall moleculePhase 2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
36/ 100
Competitive Position
65/ 100

Competitive context

133 Active assets in the Stroke cohort.

Asset / SponsorPhaseRating
Aggrenox
Boehringer Ingelheim
Phase 4BBB
INCOBOTULINUMTOXINA
Parc de Salut Mar
Phase 4BBB
ATENOLOL
Northern California Institute of Research and Education
Phase 4BBB
Dextromethorphan
University of Florida
Phase 4BBB
Nerinetide
NoNO Inc.
Phase 3BBB

View all 50 →

Same molecule, other indications

PBR-06 is also rated in:

relapsing-remitting multiple sclerosisDormant
CCC
Indicative ·
55 / 100
View asset →
multiple sclerosisDormant
CC
Indicative ·
45 / 100
View asset →
Alzheimer diseaseDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →